Sugi Predict

Sugi Predict / Compounds / SCHEMBL960904

SCHEMBL960904

SCHEMBL960904

Cc1c(Cc2ccnc(N)c2F)c(=O)oc2cc(O)ccc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B3 P37058 5/20 0.56
▸ KDM4E B2RXH2 3/20 0.56
▸ GLA P06280 3/20 0.56
▸ GAA P10253 3/20 0.56
▸ NPSR1 Q6W5P4 1/20 0.56
▸ ERAP1 Q9NZ08 1/20 0.56
▸ ALDH1A1 P00352 2/20 0.50
▸ HPGD P15428 2/20 0.50
▸ CASP1 P29466 2/20 0.50
▸ CASP7 P55210 2/20 0.50
▸ HSD17B10 Q99714 2/20 0.50
▸ TSHR P16473 1/20 0.50
▸ RAF1 P04049 5/20 0.49
▸ MAP2K1 Q02750 5/20 0.49
▸ CYP2C9 P11712 2/20 0.49
▸ BRAF P15056 1/20 0.49
▸ MAP2K2 P36507 1/20 0.49
▸ MAP2K5 Q13163 1/20 0.49
▸ NQO1 P15559 1/20 0.46
▸ TP53 P04637 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30615264 1.00 HSD17B3 (0.56) HSD17B3KDM4EGLAGAANPSR1
SCHEMBL15901772 0.95 RAF1 (0.52) HSD17B3KDM4EGLAGAANPSR1
SCHEMBL26613857 0.87 HSD17B3 (0.56) HSD17B3KDM4EGLAGAANPSR1
SCHEMBL961016 0.87 HSD17B3 (0.56) HSD17B3KDM4EGLAGAANPSR1
SCHEMBL17409845 0.87 HSD17B3 (0.53) HSD17B3KDM4EGLAGAANPSR1
SCHEMBL960890 0.86 RAF1 (0.45) HSD17B3KDM4EGLAGAANPSR1
SCHEMBL962958 0.86 RAF1 (0.45) HSD17B3KDM4EGLAGAANPSR1
SCHEMBL964820 0.85 TP53 (0.49) HSD17B3KDM4EGLAGAANPSR1
SCHEMBL26613722 0.83 KDM4E (0.60) KDM4EALDH1A1HPGDHSD17B10RAF1
SCHEMBL30615270 0.83 HSD17B3 (0.51) HSD17B3KDM4EGLAGAANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250289811-A1 HETEROCYCLIC DERIVATIVES AS MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS NESTED THERAPEUTICS, INC. 2025-09-18 — — US disclosed
WO-2023211812-A1 HETEROCYCLIC DERIVATIVES AS MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS NESTED THERAPEUTICS, INC. (US) 2023-11-02 — — WO disclosed
WO-2023211812-A1 HETEROCYCLIC DERIVATIVES AS MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS NESTED THERAPEUTICS, INC. (US) 2023-11-02 — — WO disclosed
EP-2754654-B1 METHOD FOR PRODUCING COUMARIN DERIVATIVE CHUGAI PHARMACEUTICAL CO LTD (JP) 2018-05-30 — — EP disclosed
US-9133174-B2 Method for producing coumarin derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-09-15 — — US disclosed
US-9133174-B2 Method for producing coumarin derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-09-15 — — US disclosed
US-9133174-B2 Method for producing coumarin derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-09-15 — — US disclosed
US-20140213786-A1 Method for Producing Coumarin Derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2014-07-31 — — US disclosed
US-20140213786-A1 Method for Producing Coumarin Derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2014-07-31 — — US disclosed
US-20140213786-A1 Method for Producing Coumarin Derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2014-07-31 — — US disclosed
US-7897792-B2 Coumarin derivative having antitumor activity CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2011-03-01 — — US disclosed
US-20110009398-A1 p27 Protein Inducer CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2011-01-13 — — US disclosed
US-20110009398-A1 p27 Protein Inducer CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2011-01-13 — — US disclosed
US-20110009398-A1 p27 Protein Inducer CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2011-01-13 — — US disclosed
EP-2172198-A1 p27 PROTEIN INDUCER Chugai Seiyaku Kabushiki Kaisha (JP) 2010-04-07 — — EP disclosed
EP-2172198-A1 p27 PROTEIN INDUCER Chugai Seiyaku Kabushiki Kaisha (JP) 2010-04-07 — — EP disclosed
US-20100004233-A1 NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-01-07 — — US disclosed
US-20100004233-A1 NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-01-07 — — US disclosed
US-20100004233-A1 NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-01-07 — — US disclosed
EP-1982982-A1 NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2008-10-22 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140213786-A1 Method for Producing Coumarin Derivative CYP3A7, CYP2B6, CYP7A1 HSD17B3 124/4885KDM4E 3708/4885GLA 1165/4885
US-20110009398-A1 p27 Protein Inducer CDKN1A, CDK2, SKP2 HSD17B3 2321/4885KDM4E 2542/4885GLA 1210/4885
US-20100004233-A1 NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SULT1A1, SULT1E1 HSD17B3 704/4885KDM4E 2810/4885GLA 1999/4885
US-20250289811-A1 HETEROCYCLIC DERIVATIVES AS MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS MAPK1, MAP3K1, MAPK3 HSD17B3 2441/4885KDM4E 2054/4885GLA 4013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.